Urogen Pharma Ltd
NASDAQ:URGN

  • LAST PRICE
    16.7800
  • TODAY'S CHANGE (%)
    -0.1900 (-1.1196%)
  • Bid / Lots
    16.5000/ 1
  • Ask / Lots
    18.3600/ 2
  • Open / Previous Close
    17.0400 / 16.9700
  • Day Range
    16.7400
    17.2480
  • 52 Week Range
    8.6900
    24.1300
  • Volume
    1,796,559

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
URGN
Urogen Pharma Ltd
706.6M
-4.9x
---
SAGE
SAGE Therapeutics Inc
652.4M
-1.3x
---
ZYME
Zymeworks Inc
593.9M
-4.8x
---
RGNX
Regenxbio Inc
566.9M
-2.0x
---
YMAB
Y-mAbs Therapeutics Inc
527.9M
-24.4x
---
CVAC
CureVac NV
756.4M
-2.6x
---
As of 2024-06-29

Company Information

UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).

Contact Information

Headquarters
9 Ha'ta'asiya StRA'ANANA, Israel 4365007
Phone
---
Fax
---

Executives

Independent Chairman of the Board
Arie Belldegrun
President, Chief Executive Officer, Director
Elizabeth Barrett
Chief Financial Officer
Dong Kim
Chief Compliance Officer, General Counsel, Corporate Secretary
Jason Smith
Chief Commercial Officer
David Lin

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$690.1M
Revenue (TTM)
$84.3M
Shares Outstanding
41.1M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.13
EPS
$-3.39
Book Value
$-2.01
P/E Ratio
-4.9x
Price/Sales (TTM)
8.2
Price/Cash Flow (TTM)
---
Operating Margin
-82.12%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.